Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05273385 · ClinicalTrials.gov registry record · NA
Efficacy of the Nanodropper Device on Intraocular Pressure in Patients With Glaucoma
A NA study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- NA
- Development phase
- 16
- Enrollment target
NCT05273385 is a NA study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 16 participants.
The verdict
NCT05273385, a NA study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
Study Summary
Glaucoma is the leading cause of irreversible blindness worldwide. Previous studies demonstrate that smaller eye drops used in the treatment of glaucoma are just as efficacious as their larger counterparts. The proposed study hopes to demonstrate the non-inferiority of using Nanodropper to lower intraoccular pressure (IOP) in glaucoma patients compared to standard of care eye drops.
Interventions
- DEVICE Nanodropper
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2022-10-10 |
| Est. Completion | 2024-12-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05273385
The ClinicalTrials.gov registry entry for NCT05273385 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nanodropper is the first listed.
NCT05273385 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05273385 about?
NCT05273385 is a clinical study titled "Efficacy of the Nanodropper Device on Intraocular Pressure in Patients With Glaucoma". Glaucoma is the leading cause of irreversible blindness worldwide. Previous studies demonstrate that smaller eye drops used in the treatment of glaucoma are just as efficacious as their larger counterparts. The proposed study hopes to demonstrate the non-inferiority of using Nanodropper to lower int...
What is the current status of trial NCT05273385?
This trial is currently terminated. It is a NA study. The enrollment target is 16 participants. The study started on 2022-10-10. Estimated completion is 2024-12-10.
What interventions are being tested in trial NCT05273385?
The interventions under investigation include: Nanodropper (DEVICE).
Who is sponsoring clinical trial NCT05273385?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.